Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.44 |
| ▸ | GAK | O14976 | 2/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.41 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 11/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999753 | 0.93 | MAPKAPK2 (0.35) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999406 | 0.91 | MAPKAPK2 (0.52) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999478 | 0.86 | KDR (0.40) | MAPKAPK2KDRTNF | |
| SCHEMBL30180305 | 0.86 | KDR (0.40) | MAPKAPK2KDRTNF | |
| SCHEMBL23999754 | 0.85 | MAPKAPK2 (0.45) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999400 | 0.85 | MAPKAPK2 (0.43) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999474 | 0.83 | CDK6 (0.39) | MAPKAPK2KDR | |
| SCHEMBL23999402 | 0.83 | MAPKAPK2 (0.43) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999656 | 0.83 | MAPKAPK2 (0.39) | MAPKAPK2KDRTNF | |
| SCHEMBL30180578 | 0.83 | MAPKAPK2 (0.39) | MAPKAPK2KDRTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | MAPKAPK2 138/4885GAK 505/4885RIPK2 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.